Samuel Vic, Jean-Baptiste Thibert, Emmanuel Bachy, Guillaume Cartron, Thomas Gastinne, Franck Morschhauser, Fabien Le Bras, Krimo Bouabdallah, Fabien Despas, Jacques Olivier Bay, Marie-Thérèse Rubio, Mohamad Mohty, Olivier Casasnovas, Sylvain Choquet, Cristina Castilla-Llorente, Stéphanie Guidez, Michael Loschi, Blandine Guffroy, Sylvain Carras, Laurianne Drieu La Rochelle, Mathilde Guillet, Roch Houot
Chimeric antigen receptor (CAR) T-cells targeting CD19 have been approved for the treatment of relapse/refractory large B-cell lymphoma. Hematotoxicity is the most frequent CAR T-cell-related adverse event. Transfusion support is a surrogate marker of severe cytopenias. Transfusion impacts patients' quality of life, presents specific toxicities and is known to affect immunity through the so-called transfusion-related immunomodulation, that may impact CAR T-cell efficacy. We analyzed data from 671 patients from the French DESCAR-T registry for whom exhaustive transfusion data were available...
January 4, 2024: Blood Advances